SBIR/STTR Reauthorization Advances to President's Desk

The future of the SBIR/STTR programs has been a critical issue for the life sciences innovation ecosystem, as highlighted in prior biolink updates, and one that MichBio, alongside state and national partners, has actively supported through sustained advocacy for an extended period of time. 

As MichBio noted in a LinkedIn post last week, Congress has now passed legislation reauthorizing SBIR and STTR, sending the bill to the President for signature. Once enacted, the programs will be extended for a new five-year period, restoring stability to a cornerstone source of non-dilutive funding for early-stage companies. 

For Michigan’s life sciences startups, this outcome is particularly significant. SBIR/STTR funding plays a vital role in helping companies bridge early technical milestones, strengthen venture readiness, and advance innovations emerging from our state’s research institutions. 

This reauthorization reflects the collective efforts of stakeholders across the country - including MichBio and its members - to ensure continued federal investment in small business innovation. 

With long-term authorization now within reach, Michigan’s early-stage life sciences companies can move forward with greater confidence in a critical funding pathway that supports commercialization and growth.